Difference between revisions of "Team:BGU Israel"

Line 13: Line 13:
 
   <script src="https://maxcdn.bootstrapcdn.com/bootstrap/3.3.7/js/bootstrap.min.js"></script>
 
   <script src="https://maxcdn.bootstrapcdn.com/bootstrap/3.3.7/js/bootstrap.min.js"></script>
 
   <style>
 
   <style>
−
      
+
     body {
 +
      font: 400 15px Segoe UI !important;
 +
      line-height: 1.8;
 +
      color: #818181;
 +
  }
 +
  h1 {
 +
      font-size: 32px!important;
 +
      font-family: Segoe UI Light!important;
 +
      text-transform: uppercase;
 +
      color: #303030;
 +
      font-weight: 600;
 +
      margin-bottom: 30px !important;
 +
  }
 +
  h4 {
 +
      font-size: 19px;
 +
      line-height: 1.375em;
 +
      color: #303030;
 +
      font-weight: 400;
 +
      margin-bottom: 30px;
 +
  } 
 +
      p, ol {
 +
          font-size: 16px !important;
 +
          padding:10px;
 +
          color:#010101 !important;
 +
      }
 +
  .jumbotron {
 +
      background-color: #f4511e;
 +
      color: #fff;
 +
      padding: 100px 25px;
 +
      font-family: Montserrat, sans-serif;
 +
  }
 +
  .container-fluid {
 +
      padding: 60px 50px;
 +
  }
 +
  .bg-grey {
 +
      background-color: #f6f6f6;
 +
  }
 +
  .logo-small {
 +
      color: #f4511e;
 +
      font-size: 50px;
 +
  }
 +
  .logo {
 +
      color: #f4511e;
 +
      font-size: 200px;
 +
  }
 +
  .thumbnail {
 +
      padding: 0 0 15px 0;
 +
      border: none;
 +
      border-radius: 0;
 +
  }
 +
  .thumbnail img {
 +
      width: 100%;
 +
      height: 100%;
 +
      margin-bottom: 10px;
 +
  }
 +
  .carousel-control.right, .carousel-control.left {
 +
      background-image: none;
 +
      color: #f4511e;
 +
  }
 +
  .carousel-indicators li {
 +
      border-color: #f4511e;
 +
  }
 +
  .carousel-indicators li.active {
 +
      background-color: #f4511e;
 +
  }
 +
  .item h4 {
 +
      font-size: 19px;
 +
      line-height: 1.375em;
 +
      font-weight: 400;
 +
      font-style: italic;
 +
      margin: 70px 0;
 +
  }
 +
  .item span {
 +
      font-style: normal;
 +
  }
 +
  .panel {
 +
      border: 1px solid #f4511e;
 +
      border-radius:0 !important;
 +
      transition: box-shadow 0.5s;
 +
  }
 +
  .panel:hover {
 +
      box-shadow: 5px 0px 40px rgba(0,0,0, .2);
 +
  }
 +
  .panel-footer .btn:hover {
 +
      border: 1px solid #f4511e;
 +
      background-color: #fff !important;
 +
      color: #f4511e;
 +
  }
 +
  .panel-heading {
 +
      color: #fff !important;
 +
      background-color: #f4511e !important;
 +
      padding: 25px;
 +
      border-bottom: 1px solid transparent;
 +
      border-top-left-radius: 0px;
 +
      border-top-right-radius: 0px;
 +
      border-bottom-left-radius: 0px;
 +
      border-bottom-right-radius: 0px;
 +
  }
 +
  .panel-footer {
 +
      background-color: white !important;
 +
  }
 +
  .panel-footer h3 {
 +
      font-size: 32px;
 +
  }
 +
  .panel-footer h4 {
 +
      color: #aaa;
 +
      font-size: 14px;
 +
  }
 +
  .panel-footer .btn {
 +
      margin: 15px 0;
 +
      background-color: #f4511e;
 +
      color: #fff;
 +
  }
 +
  .navbar {
 +
      margin-bottom: 10px; !important;
 +
      background-color: #fff !important;
 +
      z-index: 9999!important;
 +
      border: 0 !important;
 +
    text-transform:uppercase !important;
 +
      border-radius: 0 !important;
 +
      font-family: 'Segoe UI Light'!important;
 +
      font-weight: 600!important;
 +
      color:#000!important;
 +
  }
 +
  .navbar li a, .navbar .navbar-brand {
 +
      color: #000 !important;
 +
  }
 +
  .navbar-nav li a:hover, .navbar-nav li.active a {
 +
      color: #0186ac !important;
 +
      background-color: #fff !important;
 +
  }
 +
  .navbar-default .navbar-toggle {
 +
      border-color: transparent;
 +
      color: #fff !important;
 +
  }
 +
 
 +
  .slideanim {visibility:hidden;}
 +
  .slide {
 +
      animation-name: slide;
 +
      -webkit-animation-name: slide;
 +
      animation-duration: 1s;
 +
      -webkit-animation-duration: 1s;
 +
      visibility: visible;
 +
  }
 +
  @keyframes slide {
 +
    0% {
 +
      opacity: 0;
 +
      transform: translateY(70%);
 +
    }
 +
    100% {
 +
      opacity: 1;
 +
      transform: translateY(0%);
 +
    }
 +
  }
 +
  @-webkit-keyframes slide {
 +
    0% {
 +
      opacity: 0;
 +
      -webkit-transform: translateY(70%);
 +
    }
 +
    100% {
 +
      opacity: 1;
 +
      -webkit-transform: translateY(0%);
 +
    }
 +
  }
 +
  @media screen and (max-width: 768px) {
 +
    .col-sm-4 {
 +
      text-align: center;
 +
      margin: 25px 0;
 +
    }
 +
    .btn-lg {
 +
        width: 100%;
 +
        margin-bottom: 35px;
 +
    }
 +
  }
 +
  @media screen and (max-width: 480px) {
 +
    .logo {
 +
        font-size: 150px;
 +
    }
 +
  }
 +
      header.masthead {
 +
  padding-top: 10rem;
 +
  padding-bottom: calc(10rem - 56px);
 +
 
 +
  background-position: center center;
 +
  -webkit-background-size: cover;
 +
  -moz-background-size: cover;
 +
  -o-background-size: cover;
 +
  background-size: cover;
 +
}
 +
      .parallax-window {
 +
    min-height: 700px;
 +
    background: transparent;
 +
}
 +
      #abstract p, #abstract ol {
 +
          text-align: justify;
 +
      }
 +
      #myBtn {
 +
  display: none;
 +
         
 +
  position: fixed;
 +
  bottom: 20px;
 +
  right: 20px;
 +
  z-index: 99;
 +
  font-size: 16px;
 +
  border: none;
 +
  outline: none;
 +
  background-color: #0186ac;
 +
  color: white;
 +
  cursor: pointer;
 +
  padding: 8px 15px 8px 15px;
 +
  border-radius: 100px;
 +
}
 +
 
 +
#myBtn:hover {
 +
  background-color: #555;
 +
}
 +
      footer {
 +
          background-color:#262626;
 +
          color:#fff !important;
 +
      }
 +
 
 
     </style>
 
     </style>
 
</head>
 
</head>

Revision as of 09:30, 29 July 2018

OriginALS

OriginALS

Abstract

Recent research studies of Amyotrophic Lateral Sclerosis (ALS) suggest that brain cells that have become toxic, directly contribute to the progression of the disease. These cells change their gene expression pattern and possess distinguishing genetic markers. In addition, they drive the death of other cells in the brain among them the motor neurons.

Our objective, as the BGU-IGEM team OriginALS, is to prolong survival of ALS patients via a novel genetic engineering approach. In order to reach this objective, we combine two separate strategies as our therapeutic approach:

  1. We identify and selectively eliminate only the toxic cells. In order to identify and target the toxic-cells only, we use distinguishing markers that are unique only to them.
  2. We prevent the generation of new toxic cells by genetically targeting specific molecules that generate the toxic cells.

In conclusion, our approach combines an apoptotic destruction of toxic cells with the prevention of the formation of new toxic cells, thus aiming to significantly reduce the occurrence of toxic cells in the central neuronal system (CNS), which is aimed at a significant deceleration of the progression rate of ALS.